Effect of Ipragliflozin, a new oral hypoglycemic agent, on body composition in patients with diabetes

Effect of Ipragliflozin, a new oral hypoglycemic agent, on body composition in patients with diabetes - Effect of Ipragliflozin on body composition

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014775

Enrollment

Registered

2014-08-15

Start date

2014-08-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Ipragliflozin Metformin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients without severe complications patients who can do diet and exercise therapy

Exclusion criteria

Exclusion criteria: Contraindication for Ipragliflozin Patients who had been treated with metformin or GLP-1 analogues Pregnant woman

Design outcomes

Primary

Measure	Time frame
Lean body mass	—

Secondary

Measure	Time frame
body weight fasting plasma glucose HbA1c free fatty acid (24 fraction)	—

Countries

Japan

Contacts

Public ContactToshihide Kawai

Keio University School of Medicine Internal Medicine & Institute for Integrated Sports Medicine

tkawai@keio.jp03-3353-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026